z-logo
Premium
Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer?
Author(s) -
Fay André P.,
Bellmunt Joaquim
Publication year - 2015
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13070
Subject(s) - medicine , angiogenesis , prostate cancer , bevacizumab , docetaxel , enzalutamide , oncology , sunitinib , endoglin , cancer , vascular endothelial growth factor , cabazitaxel , metastasis , cancer research , chemotherapy , androgen deprivation therapy , vegf receptors , androgen receptor , stem cell , biology , cd34 , genetics

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom